Synexa Life Sciences is proud to welcome Paul Holme to its Global Management Team as Chief Operating Officer (COO).
Paul brings over 34 years of extensive experience in the pharmaceutical and CRO sectors, having held senior leadership roles in both discovery and regulatory bioanalysis. His career has been defined by his expertise in toxicology, DMPK, and regulatory bioanalysis, as well as his ability to lead and optimise high-performing teams in both large pharma and contract research environments.
Most recently, Paul served as CEO and co-founder of Alderley Analytical, a Regulatory Bioanalysis CRO based near Manchester, UK. Under his leadership as CEO, Alderley Analytical grew into a successful organisation, culminating in its acquisition by Synexa Life Sciences in October 2024. Prior to this, Paul held the position of Director of Regulatory Bioanalysis at AstraZeneca, where he contributed to advancing global bioanalysis strategies.
In his new role as COO at Synexa, Paul will focus on driving operational excellence, enhancing quality and efficiency, and fostering collaboration across global teams. His proven ability to scale organisations and build high-performing teams will be instrumental as Synexa continues to expand its capabilities and deliver world-class biomarker solutions to its customers.
